Acta Med. 2022, 65: 119-124

https://doi.org/10.14712/18059694.2023.1

Current Status, Prevention and Treatment of BK Virus Nephropathy

Ester KurašováaID, Jakub Štěpána, Karel Krejčía, František Mrázekb, Pavel Sauerc, Jana Janečkovád, Tomáš Tichýe

aUniversity Hospital Olomouc and Palacký University Olomouc, Faculty of Medicine and Dentistry, Department of Internal Medicine III – Nephrology, Rheumatology and Endocrinology, Olomouc, Czech Republic
bUniversity Hospital Olomouc and Palacký University Olomouc, Faculty of Medicine and Dentistry, Department of Immunology, Olomouc, Czech Republic
cUniversity Hospital Olomouc and Palacký University Olomouc, Faculty of Medicine and Dentistry, Department of Microbiology, Olomouc, Czech Republic
dUniversity Hospital Olomouc and Palacký University Olomouc, Faculty of Medicine and Dentistry, Department of Surgery II, Olomouc, Czech Republic
eUniversity Hospital Olomouc and Palacký University Olomouc, Faculty of Medicine and Dentistry, Department of Clinical and Molecular Pathology, Olomouc, Czech Republic

Received June 12, 2022
Accepted January 19, 2023

References

1. Zaman RA, Ettenger RB, Cheam H, et al. A novel treatment regimen for BK viremia. Transplantation 2014 Jun 15; 97(11): 1166–71. <https://doi.org/10.1097/01.TP.0000441825.72639.4f>
2. Calvignac-Spencer S, Feltkamp MC, Daugherty MD et al. A taxonomy update for the family Polyomaviridae. Arch Virol 2016 Jun; 161(6): 1739–50. <https://doi.org/10.1007/s00705-016-2794-y>
3. Zhong S, Randhawa PS, Ikegaya H, et al. Distribution patterns of BK polyomavirus (BKV) subtypes and subgroups in American, European and Asian populations suggest co-migration of BKV and the human race. J Gen Virol 2009 Jan; 90(Pt 1): 144–52. <https://doi.org/10.1099/vir.0.83611-0>
4. Pinto M, Dobson S. BK and JC virus: a review. J Infect 2014 Jan; 68(Suppl 1): S2–8. <https://doi.org/10.1016/j.jinf.2013.09.009>
5. Cohen-Bucay A, Ramirez-Andrade SE, Gordon CE, et al. Advances in BK Virus Complications in Organ Transplantation and Beyond. Kidney Med 2020 Oct 11; 2(6): 771–86. <https://doi.org/10.1016/j.xkme.2020.06.015> <PubMed>
6. Huang Y, Chen XT, Yang SC, et al. Detection of Proximal Tubule Involvement by BK Polyomavirus in Kidney Transplant Recipients with Urinary Sediment Double-Immunostaining. Front Immunol 2020 Sep 23; 11: 582678. <https://doi.org/10.3389/fimmu.2020.582678> <PubMed>
7. Moriyama T, Sorokin A. BK virus (BKV): infection, propagation, quantitation, purification, labeling, and analysis of cell entry. Curr Protoc Cell Biol 2009 Mar; Chapter 26:Unit 26.2.
8. Lamarche C, Orio J, Collette S, et al. BK Polyomavirus and the Transplanted Kidney: Immunopathology and Therapeutic Approaches. Transplantation 2016 Nov; 100(11): 2276–87. <https://doi.org/10.1097/TP.0000000000001333> <PubMed>
9. Chancharoenthana W, Leelahavanichkul A. Innate Immunity Response to BK Virus Infection in Polyomavirus-Associated Nephropathy in Kidney Transplant Recipients. Transplantology 2022; 3: 20–32. <https://doi.org/10.3390/transplantology3010003>
10. Chon WJ, Aggarwal N, Kocherginsky M, Kane B., Sutor J, Josephson AM. High-level viruria as a screening tool for BK virus nephropathy in renal transplant recipients. Kidney Res Clin Pract 2016 Sep; 35(3): 176–81. <https://doi.org/10.1016/j.krcp.2016.05.005> <PubMed>
11. Manzano Sánchez D, Jimeno García L, López Jiménez I, et al. Renal Function Impairment in Kidney Transplantation: Importance of Early BK Virus Detection. Transplant Proc 2019 Mar; 51(2): 350–2. <https://doi.org/10.1016/j.transproceed.2018.12.016>
12. Egli A, Binggeli S, Bodaghi S, et al. Cytomegalovirus and polyomavirus BK posttransplant. Nephrol Dial Transplant 2007 Sep; 22 Suppl 8: 72–82. <https://doi.org/10.1093/ndt/gfm648>
13. Krejci K, Tichy T, Bednarikova J, Zamboch K, Zadrazil J. BK virus-induced renal allograft nephropathy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2018 Sep; 162(3): 165–77. <https://doi.org/10.5507/bp.2018.018>
14. Lorant C, Westman G, Bergqvist A, von Zur-Mühlen B, Eriksson BM. Risk Factors for Developing BK Virus-Associated Nephropathy: A single-center retrospective cohort study of kidney transplant recipients. Ann Transplant 2022; 27: e934738.
15. Sachdeva MS, Nada R, Jha V, Sakhuja V, Joshi K. The high incidence of BK polyoma virus infection among renal transplant recipients in India. Transplantation 2004 Feb 15; 77(3): 429–31. <https://doi.org/10.1097/01.TP.0000113163.02039.30>
16. Van Aalderen MC, Heutinck KM, Huisman C, ten Berge IJ. BK virus infection in transplant recipients: clinical manifestations, treatment options and the immune response. Neth J Med 2012 May; 70(4): 172–83.
17. Helanterä I, Hirsch HH, Wernli M, et al. Simultaneous BK Polyomavirus (BKPyV)-associated nephropathy and hemorrhagic cystitis after living donor kidney transplantation. J Clin Virol 2016 Mar; 76: 4–7. <https://doi.org/10.1016/j.jcv.2015.12.008>
18. Everly MJ, Briley KP, Haisch CE, et al. Racial differences in incident de novo donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort study. Transpl Int 2017; 30(6): 566–78. <https://doi.org/10.1111/tri.12937>
19. Sawinski D, Forde KA, Trofe-Clark J, et al. Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodies. J Am Soc Nephrol 2015; 26(4): 966–75. <https://doi.org/10.1681/ASN.2014010119> <PubMed>
20. Gera DN, Shah MK, Ghodela VA, Kute VB, Trivedi HL. De Novo Collapsing Glomerulopathy in Renal Allograft in Association with BK Virus Nephropathy in a Child and Stabilization of Renal Function by Elimination of Viremia. Indian J Nephrol 2017; 27(3): 228–30. <https://doi.org/10.4103/0971-4065.200516> <PubMed>
21. Chikeka IO, Paulk A, Haririan A, Papadimitriou JC, Drachenberg CB. Concurrent cytomegalovirus glomerulitis and BK polyomavirus-associated nephropathy in a kidney allograft biopsy. Transpl Infect Dis 2016; 18(2): 247–50. <https://doi.org/10.1111/tid.12498>
22. El-Mouallem NJ, Paul AK. BK Virus–Associated Urinary Bladder Cancer in a Kidney Transplant Recipient: A Case Report and Review of the Pathogenesis. Am J Hematol Oncol 2017; 13(3): 15–20.
23. Salvatore SP, Myers-Gurevitch PM, Chu S, Robinson BD, Dadhania D, Seshan SV. Polyoma (BK) virus associated urothelial carcinoma originating within a renal allograft five years following resolution of polyoma virus nephropathy. Clin Nephrol 2016; 85(3): 179–83. <https://doi.org/10.5414/CN108410>
24. Jun JB, Choi Y, Kim H, Lee SH, Jeong J, Jung J. BK polyomavirus encephalitis in a patient with thrombotic microangiopathy after an allogeneic hematopoietic stem cell transplant. Transpl Infect Dis 2016 Dec; 18(6): 950–3. <https://doi.org/10.1111/tid.12620>
25. Roy S, Mieczkowski PA, Weida, C, et al. BK polyomavirus nephropathy with systemic viral spread: Whole genome sequencing data from a fatal case of BKPyV infection. Transplant Infect Dis 2020 Apr; 22(2): e13269. <https://doi.org/10.1111/tid.13269>
26. Hodowanec AC, Simon DM. BK virus screening and management practices among US renal transplant programs: a survey. Transpl Int 2015; 28(11): 1339–41. <https://doi.org/10.1111/tri.12602>
27. Cohen-Bucay A, Ramirez-Andrade SE, Gordon CE, Francis JM, Chitalia VC. Advances in BK Virus Complications in Organ Transplantation and Beyond. Kidney Med 2020 Oct 11; 2(6): 771–86. <https://doi.org/10.1016/j.xkme.2020.06.015> <PubMed>
28. Funk GA, Gosert R, Comoli P, Ginevri F, Hirsch HH. Polyomavirus BK replication dynamics in vivo and in silico to predict cytopathology and viral clearance in kidney transplants. Am J Transplant 2008; 8(11): 2368–77. <https://doi.org/10.1111/j.1600-6143.2008.02402.x>
29. Chon WJ, Aggarwal N, Kocherginsky M, Kane B, Sutor J, Josephson MA. High-level viruria as a screening tool for BK virus nephropathy in renal transplant recipients. Kidney Res Clin Pract 2016; 35(3): 176–81. <https://doi.org/10.1016/j.krcp.2016.05.005> <PubMed>
30. Krejci K, Tichy T, Bednarikova J, et al. Nephrotoxicity of calcineurin inhibitors as a risk factor for BK polyomavirus replication after kidney transplantation. J Med Virol 2021 Jun; 93(6): 3871–9. <https://doi.org/10.1002/jmv.26520>
31. Boan P, Hewison C, Swaminathan R, et al. Optimal use of plasma and urine BK viral loads for screening and predicting BK nephropathy. BMC Infect Dis 2016 Jul 22; 16: 342. <https://doi.org/10.1186/s12879-016-1652-6> <PubMed>
32. Boran M, Yıldırım T, Boran E, Boran M, Kilic H. Late-Onset BK Viruria in Renal Transplant Recipients. Transplant Proc 2015; 47(6): 1786–9. <https://doi.org/10.1016/j.transproceed.2015.06.028>
33. Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005 May 27; 79(10): 1277–86. <https://doi.org/10.1097/01.TP.0000156165.83160.09>
34. Govind S, Hockley J, Morris C. Collaborative Study Group. 2015. Collaborative Study to establish the 1st WHO International Standard for BKV DNA for nucleic acid amplification technique (NAT)-based assays. WHO/BS/2015.2270. WHO, Geneva, Switzerland. Available from: http://apps.who.int/iris/handle/10665/197764
35. Nankivell BJ, Renthawa J, Jeoffreys N, et al. Clinical Utility of Urinary Cytology to Detect BK Viral Nephropathy. Transplantation 2015; 99(8): 1715–22. <https://doi.org/10.1097/TP.0000000000000642>
36. Hassan S, Mittal C, Amer S, et al. Currently recommended BK virus (BKV) plasma viral load cutoff of ≥4 log10/mL underestimates the diagnosis of BKV-associated nephropathy: a single transplant center experience. Transpl Infect Dis 2014; 16(1): 55–60. <https://doi.org/10.1111/tid.12164>
37. Kien TQ, Kien NX, Thang LV, et al. Stepwise Reduction of Mycophenolate Mofetil with Conversion to Everolimus for the Treatment of Active BKV in Kidney Transplant Recipients: A Single-Center Experience in Vietnam. J Clin Med 2022 Dec 8; 11(24): 7297. <https://doi.org/10.3390/jcm11247297> <PubMed>
38. Salinas T, Li C, Snopkowski C, et al. Urinary cell mRNA profiling of kidney allograft recipients: Development of a portable protocol for noninvasive diagnosis of T cell mediated rejection and BK virus nephropathy. J Immunol Methods 2023 Jan; 512: 113402. <https://doi.org/10.1016/j.jim.2022.113402>
39. Kamel M, Kadian M, Salazar MN, et al. A Case of BK Nephropathy without Detectable Viremia or Viruria. Am J Case Rep 2015; 16: 532–5. <https://doi.org/10.12659/AJCR.894314> <PubMed>
40. Castro T, Fink MC, Figueiredo M, et al. Polyomavirus BK and JC in individuals with chronic kidney failure, kidney transplantation, and healthy controls. J Clin Virol 2017; 89: 5–9. <https://doi.org/10.1016/j.jcv.2017.02.003>
41. Singh HK, Reisner H, Derebail VK, Kozlowski T, Nickeleit V. Polyomavirus nephropathy: quantitative urinary polyomavirus-Haufen testing accurately predicts the degree of intrarenal viral disease. Transplantation 2015; 99(3): 609–15. <https://doi.org/10.1097/TP.0000000000000367> <PubMed>
42. Dadhania D, Snopkowski C, Ding R, et al. Validation of noninvasive diagnosis of BK virus nephropathy and identification of prognostic biomarkers. Transplantation 2010; 90(2): 189–97. <https://doi.org/10.1097/TP.0b013e3181e2a932> <PubMed>
43. Demey B, Descamps V, Presne C, et al. BK Polyomavirus Micro-RNAs: Time Course and Clinical Relevance in Kidney Transplant Recipients. Viruses 2021; 13: 351. <https://doi.org/10.3390/v13020351> <PubMed>
44. Randhawa P, Pastrana DV, Zeng G, et al. Commercially available immunoglobulins contain virus neutralizing antibodies against all major genotypes of polyomavirus BK. Am J Transplant 2015; 15(4): 1014–20. <https://doi.org/10.1111/ajt.13083> <PubMed>
45. Hirsch HH, Randhawa PS. AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019 Sep; 33(9): e13528.
46. Krajewski W, Kamińska D, Poterek A, et al. Pathogenicity of BK virus on the urinary system. Cent European J Urol 2020; 73(1): 94–103.
47. Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005 Mar; 5(3): 582–94. <https://doi.org/10.1111/j.1600-6143.2005.00742.x>
48. Kasiske BL, Zeier MG, Chapman JR, et al. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010 Feb; 77(4): 299–311. <https://doi.org/10.1038/ki.2009.377>
49. Drachenberg CB, Papadimitriou JC, Chaudhry MR, et al. Histological Evolution of BK Virus-Associated Nephropathy: Importance of Integrating Clinical and Pathological Findings. Am J Transplant 2017 Aug; 17(8): 2078–91. <https://doi.org/10.1111/ajt.14314>
50. Solez K, Colvin RB, Racusen LC, et al. Banff ’05 meeting report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (“CAN”). Am J Transplant 2007; 7: 518–26. <https://doi.org/10.1111/j.1600-6143.2006.01688.x>
51. Loupy A, Mengel M, Haas M. Thirty years of the International Banff Classification for Allograft Pathology: the past, present, and future of kidney transplant diagnostics. Kidney Int 2022 Apr; 101(4): 678–91. <https://doi.org/10.1016/j.kint.2021.11.028>
52. Nankivell BJ, Renthawa J, Sharma RN, Kable K, O’Connell PJ, Chapman JR. BK Virus Nephropathy: Histological Evolution by Sequential Pathology. Am J Transplant 2017; 17(8): 2065–77. <https://doi.org/10.1111/ajt.14292>
53. Kowalewska J, El Moudden I, Perkowska-Ptasinska A, et al. Assessment of the Banff Working Group classification of definitive BK polyomavirus nephropathy. Transpl Int 2021; 34(11): 2286–96. <https://doi.org/10.1111/tri.14003>
54. Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell-mediated rejection, anti- body-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant 2018; 18(2): 293–307. <https://doi.org/10.1111/ajt.14625> <PubMed>
55. Adam BA, Kikic Z, Wagner S, et al. Intragraft gene expression in native kidney BK virus nephropathy versus T cell-mediated rejection: Prospects for molecular diagnosis and risk prediction. Am J Transplant 2020 Dec; 20(12): 3486–501. <https://doi.org/10.1111/ajt.15980>
56. Bischof N, Hirsch HH, Wehmeier C, et al. Reducing calcineurin inhibitor first for treating BK polyomavirus replication after kidney transplantation: long-term outcomes. Nephrol Dial Transplant 2019 Jul 1; 34(7): 1240–50. <https://doi.org/10.1093/ndt/gfy346>
57. Huang J, Danovitch G, Pham PT, Bunnapradist S, Huang E. Kidney retransplantation for BK virus nephropathy with active viremia without allograft nephrectomy. J Nephrol 2015; 28(6): 773–7. <https://doi.org/10.1007/s40620-015-0200-6>
58. Sood P, Senanayake S, Sujeet K, et al. Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study. Transplantation 2012 Oct 27; 94(8): 814–21. <https://doi.org/10.1097/TP.0b013e31826690c6>
59. Chen XT, Li J, Deng RH, et al. The therapeutic effect of switching from tacrolimus to low-dose cyclosporine A in renal transplant recipients with BK virus nephropathy. Biosci Rep 2019 Feb 22; 39(2): BSR20182058. <https://doi.org/10.1042/BSR20182058> <PubMed>
60. NCT02758288 – BK Viremia and BK Virus Nephropathy Post Kidney Transplant Comparison of New Practices with Traditional Approach: A Combined Retrospective Chart Review and Prospective Observational Study.
61. Kuten SA, Patel SJ, Knight RJ, et al. Observations on the use of cidofovir for BK virus infection in renal transplantation. Transpl Infect Dis 2014; 16: 975–83 <https://doi.org/10.1111/tid.12313>
62. Iturriza-Gomara M, O’Brien SJ. Foodborne viral infections. Curr Opin Infect Dis 2016; 29: 495–501. <https://doi.org/10.1097/QCO.0000000000000299>
63. Nelson AS, Heyenbruch D, Rubinstein JD, et al. Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients. Blood Adv 2020; 4: 5745–54.
64. NCT04605484 – Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients with BK Viremia
65. NCT04294472 – A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients.
66. Jordan S, Limaye AP, Fischbach B, et al. A Randomized Phase 2 Study of Mau868 Vs Placebo to Treat Bk Viremia In Kidney Transplant Recipients (abstract). Am J Transplant 2022; 22 (Suppl 3).
67. Kesherwani V, Tarang S. An immunoinformatic approach to universal therapeutic vaccine design against BK virus. Vaccine 2019; 37(26): 3457–63. <https://doi.org/10.1016/j.vaccine.2019.04.096>
68. NCT03576014 – Evaluate Tolerability and Safety of BD03 for Prevention of CMV and BKV Reactivation in Kidney Transplant Recipient.
69. TG. Aicuris licences antisense RNA know-how from Hybridize Therapeutics. European Biotechnology 2022 Feb 10. Available at: https://european-biotechnology.com/up-to-date/latest-news/news/aicuris-licences-antisense-rna-know-how-from-hybridize-therapeutics.html
70. AiCuris and Hybridize Therapeutics enter worldwide license agreement of up to €100M for a direct-acting RNA-based therapy against BK Virus. February 9, 2022. Available at: https://hybridizetherapeutics.com/news/aicuris_hybridize
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive